Eccogene

Eccogene, also commonly referred to as Chengyi Biopharma, is a clinical-stage biotechnology company focused on developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. Founded in 2018 and headquartered in Shanghai, the company leverages its expertise in translational research and medicinal chemistry to target diseases such as obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). The company gained significant global attention in late 2023 when it out-licensed its lead asset, ECC5004—a potent, once-daily oral GLP-1 receptor agonist—to AstraZeneca in a multi-billion dollar agreement. Eccogene maintains a robust internal pipeline, including selective THR-beta full agonists and SSAO inhibitors currently in Phase 2 clinical development. The company is backed by premier life science investors including Lilly Asia Ventures, Qiming Venture Partners, and Sequoia China.